Finasteride: Treatment of Benign Prostate Hyperplasia

Mechanism of Action of Finasteride

Finasteride is a selective competitive inhibitor of 5α-reductase type 2 of the prostate, seminal vesicles and skin. The inhibition lowers the concentration of dihydrotestosterone (DHT) in the prostate. Since DHT causes the androgenic effect in the prostate, the inhibition of 5α-reductase leads to a reduction in prostate volume. Furthermore, finasteride is used to treat male pattern baldness.

Indications for Finasteride

Finasteride is indicated in lower urinary tract symptoms or bleeding due to benign prostate hyperplasia.

Pharmacokinetics of Finasteride

After metabolization, the metabolites are excreted via the urine and stool. No dosage reduction is necessary in renal insufficiency. Experiences in dialysis patients are not available.